CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
ConditionCNS Lymphoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRoyal Marsden NHS Foundation Trust
About this trial
A prospective imaging and translational tissue study in CNS lymphoma to enable further disease characterisation and the development of potential predictive and prognostic biomarkers.
Eligibility criteria
Qualifiers
Subjects capable of giving informed consent, or if appropriate, if subject's capacity is deemed limited due to CNS involvement, a consultee can provide consent on their behalf. Some patients with PCNSL may be incapable of providing their own consent due to the neurological effects of their disease. In these cases the patient will be classed as an incapacitated adult and a legal representative will be sought in accordance with English or Scottish law as applicable (see 7.2.1)
A radiological or histological diagnosis of primary CNS lymphoma.
Have not received prior CNS directed therapy. Prior use of steroids is permitted.
Participants aged ≥18 years old.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
36 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov